伊匹单抗加尼伐单抗联合免疫疗法对转移性肌纤维肉瘤的疗效。

IF 0.9 Q4 ONCOLOGY
Rare Tumors Pub Date : 2024-11-06 eCollection Date: 2024-01-01 DOI:10.1177/20363613241290788
Foteini Kalofonou, Andrea Napolitano, Charlotte Benson, Aisha Miah, Shane Zaidi, Daniel Lindsay, Khin Thway, Robin L Jones
{"title":"伊匹单抗加尼伐单抗联合免疫疗法对转移性肌纤维肉瘤的疗效。","authors":"Foteini Kalofonou, Andrea Napolitano, Charlotte Benson, Aisha Miah, Shane Zaidi, Daniel Lindsay, Khin Thway, Robin L Jones","doi":"10.1177/20363613241290788","DOIUrl":null,"url":null,"abstract":"<p><p>We present the case of a patient with Myxofibrosarcoma (MFS), a mesenchymal type of soft tissue sarcoma (STS) and the response to combination immunotherapy with anti PD-1 and anti-CTLA-4 therapy, following disease progression after Standard chemotherapy (SACT) and Radiotherapy (RT). We have shown a timeline of treatment and responses, as well as the overall safety profile and the management of immunotherapy related adverse events. This study demonstrates the potential of checkpoint inhibitors as therapeutic agents in the treatment of MFS.</p>","PeriodicalId":46078,"journal":{"name":"Rare Tumors","volume":"16 ","pages":"20363613241290788"},"PeriodicalIF":0.9000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542115/pdf/","citationCount":"0","resultStr":"{\"title\":\"The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic myxofibrosarcoma.\",\"authors\":\"Foteini Kalofonou, Andrea Napolitano, Charlotte Benson, Aisha Miah, Shane Zaidi, Daniel Lindsay, Khin Thway, Robin L Jones\",\"doi\":\"10.1177/20363613241290788\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We present the case of a patient with Myxofibrosarcoma (MFS), a mesenchymal type of soft tissue sarcoma (STS) and the response to combination immunotherapy with anti PD-1 and anti-CTLA-4 therapy, following disease progression after Standard chemotherapy (SACT) and Radiotherapy (RT). We have shown a timeline of treatment and responses, as well as the overall safety profile and the management of immunotherapy related adverse events. This study demonstrates the potential of checkpoint inhibitors as therapeutic agents in the treatment of MFS.</p>\",\"PeriodicalId\":46078,\"journal\":{\"name\":\"Rare Tumors\",\"volume\":\"16 \",\"pages\":\"20363613241290788\"},\"PeriodicalIF\":0.9000,\"publicationDate\":\"2024-11-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11542115/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Rare Tumors\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/20363613241290788\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rare Tumors","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/20363613241290788","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

我们介绍了一名患有间充质类型软组织肉瘤(STS)--肌纤维肉瘤(MFS)的患者的病例,以及在标准化疗(SACT)和放疗(RT)后病情进展的患者对抗PD-1和抗CTLA-4联合免疫疗法的反应。我们展示了治疗和反应的时间表,以及总体安全性和免疫疗法相关不良事件的处理情况。这项研究证明了检查点抑制剂作为治疗药物治疗 MFS 的潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
The efficacy of combination immunotherapy with ipilimumab plus nivolumab in metastatic myxofibrosarcoma.

We present the case of a patient with Myxofibrosarcoma (MFS), a mesenchymal type of soft tissue sarcoma (STS) and the response to combination immunotherapy with anti PD-1 and anti-CTLA-4 therapy, following disease progression after Standard chemotherapy (SACT) and Radiotherapy (RT). We have shown a timeline of treatment and responses, as well as the overall safety profile and the management of immunotherapy related adverse events. This study demonstrates the potential of checkpoint inhibitors as therapeutic agents in the treatment of MFS.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Rare Tumors
Rare Tumors ONCOLOGY-
CiteScore
1.50
自引率
0.00%
发文量
15
审稿时长
15 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信